Healthcare - Friday, December 18, 2009 15:36 - 0 Comments

Neostem, Inc. NBS Market Open’s Down 0.01% in Morning Session

Neostem, Inc. is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is expanding into research, medical tourism, and China for the commercialization of regenerative medicine and other stem cell applicatons. In late October, NeoStem completed its acquisition of China Biopharmaceuticals, which resulted in a controlling 51% interest in Suzhou Erye Pharmaceuticals (Erye) and established three business for the Company (US + China stem cells and China pharmaceuticals focused on antibiotics and active pharmaceutical ingredients.

Last Trade: 1.46
Trade Time: 10:14am ET
Change: Down 0.00 (0.01%)
Prev Close: 1.46
Open: 1.45
Day’s Range: 1.45 – 1.46
52wk Range: 0.41 – 2.72
Volume: 6,775
Avg Vol (3m): 31,544.6
Market Cap: 53.30M

About Neostem, Inc.

NeoStem, Inc., together with its subsidiaries, operates a network of commercial autologous adult stem cell banks in the metropolitan areas of the United States. It provides adult stem cell processing, collection, cryopreservation, and banking services. Stem cells are used to treat various serious diseases and conditions, including cardiac disease, autoimmune disorders, lupus, multiple sclerosis, peripheral vascular diseases, age related musculoskeletal disorders, diabetes, cancer, neurological disease, and wound healing. The company has a strategic alliance with New England Cryogenic Center, Inc. to provide processing and storage capacity for consumers on the East Coast, and process and store for research purposes; and with UTEK Corporation to identify and isolate stem cells from adult human bone marrow called very small embryonic-like stem cells.